基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
SLC31A1 在乳腺癌预后和免疫浸润中的作用：一个新见解
英文原题：Role of SLC31A1 in prognosis and immune infiltration in breast cancer: a novel insight.
查看英文原题
Role of SLC31A1 in prognosis and immune infiltration in breast cancer: a novel insight.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们的研究强调了进一步研究的重要性，以探索靶向 SLC31A1 的治疗潜力，并揭示其在 BRCA 中除已知的耐药、自噬、铁死亡和铜死亡机制之外的额外作用。
研究思路结论见上方概要
目的
铜是人类必需的金属元素，在肿瘤预后和免疫中发挥重要作用。SLC31A1是一种高亲和力铜转运蛋白，有助于调节铜稳态，并通过耐药、自噬、铁死亡和铜死亡等机制与肿瘤预后相关。然而，SLC31A1在乳腺癌（BRCA）中的作用及其与肿瘤免疫浸润的关联尚未完全阐明。本研究旨在探讨SLC31A1在BRCA中的表达模式、临床意义及其对肿瘤免疫浸润的影响。
方法
我们综合分析了多个数据集，包括基因表达谱交互分析（GEPIA）、肿瘤免疫评估资源（TIMER）、UALCAN和Kaplan-Meier（KM）绘图仪，以评估SLC31A1在BRCA中的表达及其预后价值。此外，使用TIMER和TISIDB探讨了SLC31A1表达与肿瘤免疫浸润程度之间的相关性。
结果
SLC31A1在BRCA组织中较邻近非肿瘤组织显著上调。SLC31A1表达水平较高与较差的临床结局相关。多因素Cox回归分析证实，SLC31A1可作为独立预后指标。此外，SLC31A1表达与多种免疫调节因子、趋化因子、趋化因子受体和TIL（肿瘤浸润淋巴细胞）（TILs）显著相关，包括CD8+ T细胞、CD4+ T细胞、调节性T细胞（Tregs）、滤泡辅助性T细胞（Tfh）、中性粒细胞、M2巨噬细胞、肿瘤相关巨噬细胞（TAMs）和单核细胞。这些发现提示，SLC31A1可能调控BRCA中的巨噬细胞极化和T细胞耗竭，从而促进免疫逃逸和不良预后。
展开英文摘要原文
OBJECTIVE
Copper, an essential metal element for humans, plays vital functions in cancer prognosis and immunity. SLC31A1, a high-affinity copper transporter, helps regulate copper homeostasis and has been implicated in tumor prognosis through mechanisms such as drug resistance, autophagy, ferroptosis, and cuproptosis. However, the role of SLC31A1 in breast cancer (BRCA) and its association with tumor immune infiltration has not been fully elucidated. This study aimed to investigate the expression pattern of SLC31A1, its clinical significance, and its effect on tumor immune infiltration in BRCA.
METHODS
We comprehensively analyzed multiple datasets, including Gene Expression Profiling Interaction Analysis (GEPIA), Tumor Immune Estimation Resource (TIMER), UALCAN, and Kaplan-Meier (KM) plotter, to assess the expression of SLC31A1 and its prognostic value in BRCA. Additionally, TIMER and TISIDB were used to explore the correlation between SLC31A1 expression and the extent of tumor immune infiltration.
RESULTS
SLC31A1 was significantly upregulated in BRCA tissues compared to adjacent non-tumor tissues. Higher SLC31A1 expression levels were associated with poorer clinical outcome. Multivariate Cox regression analysis confirmed that SLC31A1 served as an independent prognostic indicator. Furthermore, SLC31A1 expression showed significant associations with various immunomodulators, chemokines, chemokine receptors, and tumor-infiltrating lymphocytes (TILs), including CD8+ T cells, CD4+ T cells, regulatory T cells (Tregs), follicular helper T cells (Tfh), neutrophils, M2 macrophages, tumor-associated macrophages (TAMs), and monocytes. These findings suggest that SLC31A1 may regulate macrophage polarization and T cell exhaustion in BRCA, contributing to immune evasion and poor prognosis.
CONCLUSION
Our study underscores the importance of further research to explore the therapeutic potential of targeting SLC31A1 and to uncover its additional roles in BRCA beyond the known mechanisms of drug resistance, autophagy, ferroptosis, and cuproptosis.
论文信息
- 作者
- Luo ZH、Zhou B、Yu JY、Li H、Li Z、Ma SQ
- 第一作者单位
- Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University Changsha 410008, Hunan, The People's Republic of China.China
- 通讯作者单位
- Department of Pharmacy, Hunan Chest Hospital Changsha 4100013, Hunan, The People's Republic of China.China
- 期刊
- International journal of clinical and experimental pathology2024
- 原文标识
- PubMed 39544714 · DOI 10.62347/LOYI1808
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →